A
Acurx Pharmaceuticals, Inc.
ACXPCIK 0001736243NasdaqNon-AcceleratedSmaller ReportingEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-7.97M
Total Assets
$7.69M
Equity
$5.27M
Shares Out
2.86M
Op. Cash Flow
$-6.79M
Business
Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company developing a new class of small-molecule antibiotics that target Gram-positive bacterial DNA polymerase IIIC (pol IIIC). Its main products and pipeline include the lead oral candidate ibezapolstat for Clostridioides difficile infection and earlier-stage systemic candidates such as ACX-375C targeting MRSA, VRE and drug-resistant Streptococcus pneumoniae. Business activities are organized around discovery, preclinical optimization and clinical development programs, including Phase 1 and Phase 2 studies and IND/Regulatory interactions. Clinical development and regulatory activities occur in the U.S., Europe and other international markets with plans for multinational clinical trials and potential commercialization via pharmaceutical partnerships or licensing.
Summary from filing dated 2025-03-17
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and Development | 2 | 5 | 6 | 5 | 2 | |
| General and Administrative | 6 | 9 | 9 | 7 | 11 | |
| TOTAL OPERATING EXPENSES | 8 | 14 | 15 | 12 | 13 | |
| OPERATING LOSS | −8 | −14 | — | — | — | |
| Interest Income | 125,445 | 20,124 | — | — | — | |
| NET LOSS | −8 | −14 | −15 | −12 | −13 | |
| Basic net loss per common share | −5.32 | −17.45 | −1.15 | −1.12 | −1.49 | |
| Diluted net loss per common share | −5.32 | −17.45 | −1.15 | −1.12 | −1.49 | |
| Weighted average common shares outstanding basic | 1 | 808,168 | 13 | 11 | 9 | |
| Weighted average common shares outstanding diluted | 1 | 808,168 | 13 | 11 | 9 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash | 8 | 4 | 7 | 9 | 13 | |
| Other Receivable | 48,417 | 51,127 | 129,159 | — | — | |
| Prepaid Expenses | 85,018 | 100,123 | 105,776 | 264,955 | 295,304 | |
| TOTAL ASSETS | 8 | 4 | 8 | 9 | 13 | |
| Accounts Payable and Accrued Expenses | 2 | 3 | 3 | 2 | 843,909 | |
| TOTAL CURRENT LIABILITIES | 2 | 3 | 3 | 2 | 843,909 | |
| TOTAL LIABILITIES | 2 | 3 | 3 | 2 | 843,909 | |
| COMMITMENTS AND CONTINGENCIES | — | — | — | — | — | |
| Preferred Stock; $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding at December 31, 2025 and 2024 | — | — | — | — | — | |
| Common Stock; $0.001 par value, 250,000,000 shares authorized, 2,348,113 shares issued and outstanding at December 31, 2025 and 200,000,000 shares authorized, 851,534 shares issued and outstanding at December 31, 2024 | 2,348 | 852 | 14,468 | 11,628 | 10,216 | |
| Additional Paid-In Capital | 81 | 68 | 58 | 46 | 39 | |
| Accumulated Deficit | −75 | −67 | −53 | −39 | −27 | |
| TOTAL SHAREHOLDERS' EQUITY | 5 | 615,121 | 5 | 7 | 12 | |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | 8 | 4 | 8 | 9 | 13 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net Loss | −8 | −14 | −15 | −12 | −13 | |
| Share-Based Compensation | 1 | 3 | 3 | 3 | 5 | |
| Share-Based Payments to Vendors | 322,319 | 833,680 | 559,583 | 430,680 | 2 | |
| Other Receivable | 2,710 | 78,032 | −129,159 | — | — | |
| Prepaid Expenses | 15,105 | 5,653 | 159,179 | 30,349 | −246,695 | |
| Accounts Payable and Accrued Expenses | −408,779 | 200,404 | 980,753 | 1 | 387,978 | |
| Net Cash Used in Operating Activities | −7 | −10 | −10 | −8 | −5 | |
| Reverse Stock Split fractional share adjustment | −1,040 | — | — | — | — | |
| Proceeds from Warrant Inducement, net of issuance costs | 2 | — | — | — | — | |
| Proceeds from Warrant Exercise | 1 | 210,199 | 2 | — | — | |
| Proceeds from issuance of common stock in connection with equity line of credit purchase agreement, net of issuance costs | 4 | — | — | — | — | |
| Proceeds from 2025 March Registered Direct Offering, net of issuance costs | 889,420 | — | — | — | — | |
| Proceeds from 2025 January Registered Direct Offering, net of issuance costs | 2 | — | — | — | — | |
| Proceeds from At-the-Market Offering, net of issuance costs | — | 6 | — | — | — | |
| Net Cash Provided by Financing Activities | 11 | 7 | 8 | 4 | 15 | |
| Net Increase/(Decrease) in Cash | 4 | −4 | −2 | −4 | 10 | |
| Share-Based Compensation to settle accrued compensation (Note 5) | 413,120 | — | — | — | — | |
| 2025 Equity Line of Credit Purchase Agreement costs (Commitment shares)(Note 4) | 360,000 | — | — | — | — | |
| 2025 Warrant Inducement Financing costs (Note 4) | 5 | — | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro